Use of Neutrophil Count in Early Diagnosis and Risk Stratification of AMI

Meißner, Julia; Irfan, Affan; Twerenbold, Raphael; Mueller, Sandra; Reiter, Miriam; Haaf, Philip; Reichlin, Tobias; Schaub, Nora; Winkler, Katrin; Pfister, Otmar; Heinisch, Corinna; Müeller, Christian

doi:10.1016/j.amjmed.2010.10.023

Cited by 35 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neutrophil blood counts have been shown previously to be an independent predictor of short-and long-term mortality after AMI. 42,43 Neutrophilia is also suggested to serve as a potential additive diagnostic biomarker for AMI in emergency patients. 44 Our results clearly demonstrate a rapid occurrence of neutrophilia within the first hour after induction of ischemia.…”

Section: Discussionmentioning

confidence: 99%

Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction

Liebetrau

Hoffmann

Dörr

et al. 2015

Circulation Research

View full text Add to dashboard Cite

In this context, high-sensitivity (hs) assays for CRP have been developed that provide both diagnostic and prognostic information. 14,15,17 Studies have shown that hs assays detect CRP concentrations with the required precision even in patients Rationale: Inflammation in the setting of acute myocardial infarction (MI) has been linked to risk stratification; however, the release kinetics of inflammatory biomarkers in patients with acute MI has been difficult to establish.Objective: The aim of this study was to determine the kinetics of changes in the levels of several biomarkers specifically linked to inflammation after transcoronary ablation of septal hypertrophy, a procedure that mimics acute MI. Methods and Results:We analyzed release kinetics of C-reactive protein, high-sensitivity C-reactive protein,

show abstract

Section: Discussionmentioning

confidence: 99%

Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction

Liebetrau

Hoffmann

Dörr

et al. 2015

Circulation Research

View full text Add to dashboard Cite

show abstract

“…Indeed, a high level of circulating neutrophils, a high neutrophil/lymphocyte ratio, as well as a raised concentration of myeloperoxidase (MPO) in patients with AMI at hospital admission have been shown to predict LV dilatation, in-stent thrombosis and cardiac death at follow-up [54,55,[78][79][80][81][82][83]. Moreover, a high number of neutrophils in circulation were shown to be a better means to predict cardiovascular mortality than a high C-reactive protein value [84].…”

Section: Neutrophilsmentioning

confidence: 99%

The cellular immune system in the post-myocardial infarction repair process

Latet

Hoymans

Herck

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…However, there is conflicting evidence about the prognostic value of neutrophils in stable CAD patients. Some reports show that elevated neutrophil count (>6 G/L) is associated with an approximately doubled risk of mortality or MACE (30, 31, 33). Others could not establish this prognostic value of neutrophils (38–40, 42) (Tables 1 and 2).…”

Section: Neutrophilsmentioning

confidence: 99%

Prognostic Value of Circulating Inflammatory Cells in Patients with Stable and Acute Coronary Artery Disease

Meeuwsen

Wesseling

Hoefer

et al. 2017

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atherosclerosis is a lipid driven chronic inflammatory disease underlying the majority of ischemic events such as myocardial infarction or stroke. Clinical management of ischemic events has improved considerably in the past decades. Accordingly, survival rates have increased. Nevertheless, 12% of patients die within 6 months after the initial event. To improve secondary prevention, appropriate risk prediction is key. However, up to date, there is no clinically available routine marker to identify patients at high risk for recurrent cardiovascular events. Due to the central role of inflammation in atherosclerotic lesion progression and destabilization, many studies have focused on the role of circulating inflammatory cells in these processes. This review summarizes the current evidence on the potential of circulating inflammatory cells as biomarkers for recurrent adverse manifestations in acute coronary syndrome and stable coronary artery disease patients.

show abstract

Use of Neutrophil Count in Early Diagnosis and Risk Stratification of AMI

Cited by 35 publications

References 23 publications

Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction

Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction

The cellular immune system in the post-myocardial infarction repair process

Prognostic Value of Circulating Inflammatory Cells in Patients with Stable and Acute Coronary Artery Disease

Contact Info

Product

Resources

About